A Phase 2 interventional study of ARQ-154 in Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 39 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dermatitis, Seborrheic with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Dermatitis, Seborrheic · United States.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 9 in phase 2, and was the 14th registered.
58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.
Browse Dermatitis, Seborrheic studies →1 of the 19 studies in Dermatitis, Seborrheic with a site in United States is open now. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 77 across 47 interventional studies indexed under Dermatitis, Seborrheic.
Median enrollment 62 across the 18 interventional studies, 32 across the 1 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
Arcutis Biotherapeutics, Inc. has 3 studies filed under Dermatitis, Seborrheic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Dermatitis, Seborrheic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks. Cohort 1 subjects are rollover subjects from study ARQ-154-203 (NCT04091646) and were rolled into treatment in the current study without interruption. Cohort 2 includes participants from ARQ-154-203 who began treatment in the current study after a gap from completing treatment in the prior study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
Cohort 1 only:
Subjects with seborrheic dermatitis who met eligibility criteria for a prior ARQ-154 study, successfully completed a prior ARQ-154 study through final visit and are able to immediately enroll into this long-term safety study on the final visit of the previous ARQ-154 study.
Cohort 2 subjects that have not participated in a prior ARQ-154 study:
Overall Assessment of Erythema and Overall Assessment of Scaling scores of Moderate ('2') at Day 1.
Cohort 2 subjects that have participated in a prior ARQ-154 study:
Exclusion Criteria:
Known or suspected:
Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members that live in the same household of enrolled subjects.
Cohort 1 only:
Subjects that use any Excluded Medication and Treatments.
Cohort 2 only:
Subjects with PHQ-8 >10 or modified PHQ-A >10 at Screening or Day 1.
Cohort 2 subjects that have participated in a prior ARQ-154 study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label, Long-term Safety of ARQ-154
Drug: ARQ-154
ARQ-154 foam 0.3% applied once daily for 52 weeks
Number of Participants With ≥1 Adverse Event (AE)
The number of participants with treatment-emergent AEs is reported. An AE is any untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to participation in the research. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.
Time frame: Up to 52 weeks
Number of Participants With ≥1 Serious Adverse Event (SAE)
The number of participants with treatment-emergent SAEs is reported. An SAE is any AE that results in death, is life-threatening (places the subject at immediate risk of death from the event as it occurred), requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject's health. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.
Time frame: Up to 52 weeks
Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear
The number of participants with an IGA score of 0 ('completely clear') or 1 ('almost clear') is presented. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
Time frame: Weeks 4, 12, 24, 36, and 52
Achievement of IGA Success
The number of participants achieving "success" in IGA assessment of disease severity is presented. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
Time frame: Weeks 4, 12, 24, 36, and 52
Duration of IGA Success
The duration of "success" in IGA assessment of disease severity is presented. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The time from first observation of IGA success to the first subsequent time a participant's disease response did not meet the criteria for IGA success is presented. The duration of IGA success for subjects who ended treatment in IGA success was censored at the last disease assessment date.
Time frame: Weeks 4, 12, 24, 36, and 52
IGA Treatment-Free Interval
The treatment-free interval is defined as time from when the participant achieves disease clearance (IGA score of 0 \["completely clear"\]) and stops treatment of all lesions until the time of restarting treatment.
Time frame: Weeks 4, 12, 24, 36, and 52
Participants were enrolled at 39 study centers in the US.
| Milestone | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|---|---|
| Started | 52 | 23 | 41 | 17 | 267 | 8 |
| Completed | 43 | 20 | 37 | 16 | 211 | 7 |
| Not completed | 9 | 3 | 4 | 1 | 56 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 4 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 1 | 1 | 29 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 | 0 | 18 | 1 |
| Withdrew: Other reason | 0 | 0 | 1 | 0 | 2 | 0 |
The number of participants with treatment-emergent AEs is reported. An AE is any untoward or unfavorable medical occurrence in a human participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to participation in the research. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.
| Participants | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Groups 3 and 4: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|
| Number of Participants With ≥1 Adverse Event (AE) | 17 | 23 | 90 | 3 |
The number of participants with treatment-emergent SAEs is reported. An SAE is any AE that results in death, is life-threatening (places the subject at immediate risk of death from the event as it occurred), requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is any other adverse event that, based upon appropriate medical judgment, may jeopardize the subject's health. Data are presented according to cohort group assigned as treatment were identical in this study regardless of the treatment received in the prior study.
| Participants | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|
| Number of Participants With ≥1 Serious Adverse Event (SAE) | 2 | 0 | 5 | 0 |
The number of participants with an IGA score of 0 ('completely clear') or 1 ('almost clear') is presented. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
| Participants | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|---|---|
| Week 4 | 36 | 7 | 20 | 10 | 137 | 5 |
| Week 12 | 35 | 7 | 25 | 12 | 172 | 5 |
| Week 24 | 31 | 10 | 24 | 11 | 177 | 3 |
| Week 36 | — | — | 0 | 0 | 37 | — |
| Week 52 | — | — | 1 | 1 | 35 | — |
The number of participants achieving "success" in IGA assessment of disease severity is presented. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
| Participants | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|---|---|
| Week 4 | 36 | 6 | 20 | 8 | 137 | 5 |
| Week 12 | 35 | 7 | 25 | 11 | 172 | 5 |
| Week 24 | 31 | 10 | 24 | 11 | 177 | 3 |
| Week 36 | 0 | 0 | 0 | 0 | 37 | 0 |
| Week 52 | 0 | 0 | 1 | 1 | 35 | 0 |
The duration of "success" in IGA assessment of disease severity is presented. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of seborrheic dermatitis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The time from first observation of IGA success to the first subsequent time a participant's disease response did not meet the criteria for IGA success is presented. The duration of IGA success for subjects who ended treatment in IGA success was censored at the last disease assessment date.
| weeks | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|---|---|
| Duration of IGA Success | 18.786 (0.14 to 32.29) | 12.143 (0.14 to 22.29) | 7.714 (0.14 to 30.43) | 13.143 (0.14 to 31.86) | 19.00 (0.14 to 50.14) | 10.00 (3.57 to 23.71) |
The treatment-free interval is defined as time from when the participant achieves disease clearance (IGA score of 0 \["completely clear"\]) and stops treatment of all lesions until the time of restarting treatment.
| weeks | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|---|---|
| IGA Treatment-Free Interval | 19.143 (0.57 to 24.00) | 11.766 (2.57 to 24.43) | 11.929 (1.14 to 22.14) | 14.143 (2.43 to 22.00) | 12.143 (0.29 to 49.14) | 20.143 (8.143 to 23.14) |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0/75 (0%) | 2/75 (2.7%) | 3/75 (4%) |
| Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0/58 (0%) | 0/58 (0%) | 4/58 (6.9%) |
| Cohort 2 Group 4: De Novo Participants | 1/267 (0.4%) | 5/267 (1.9%) | 11/267 (4.1%) |
| Cohort 1 Group 2: ARQ-154-116 Rollover | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Event | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 1/75 | 0/58 | 0/267 | 0/8 |
| Cerebrovascular accidentNervous system disorders | 1/75 | 0/58 | 0/267 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/75 | 0/58 | 1/267 | 0/8 |
| Performance status decreasedGeneral disorders | 0/75 | 0/58 | 1/267 | 0/8 |
| COVID-19 pneumoniaInfections and infestations | 0/75 | 0/58 | 1/267 | 0/8 |
| Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 0/58 | 1/267 | 0/8 |
| HypertensionVascular disorders | 0/75 | 0/58 | 1/267 | 0/8 |
| Event | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover |
|---|---|---|---|---|
| Weight decreasedInvestigations | 0/75 | 0/58 | 0/267 | 1/8 |
| TicPsychiatric disorders | 0/75 | 0/58 | 0/267 | 1/8 |
| DyspepsiaGastrointestinal disorders | 0/75 | 0/58 | 0/267 | 1/8 |
| Application site alopeciaGeneral disorders | 0/75 | 0/58 | 0/267 | 1/8 |
| Transaminases increasedInvestigations | 0/75 | 0/58 | 0/267 | 1/8 |
| Pyogenic granulomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 0/58 | 0/267 | 1/8 |
| Urinary tract infectionInfections and infestations | 0/75 | 4/58 | 3/267 | 0/8 |
| COVID-19Infections and infestations | 3/75 | 3/58 | 9/267 | 0/8 |
Efficacy data were not summarized for participants from Cohort 1 Group 2.
| Age, Continuous(years) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover | Total |
|---|---|---|---|---|---|---|---|
| Mean | 44.5 ± 15.99 | 41.0 ± 15.53 | 46.7 ± 17.20 | 48.8 ± 14.99 | 42.4 ± 16.45 | 13.5 ± 2.1 | 42.8 ± 16.8 |
| Sex: Female, Male(Participants) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover | Total |
|---|---|---|---|---|---|---|---|
| Female | 27 | 9 | 21 | 8 | 138 | 4 | 207 |
| Male | 25 | 14 | 20 | 9 | 129 | 4 | 201 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 10 | 8 | 0 | 86 | 6 | 121 |
| Not Hispanic or Latino | 41 | 13 | 33 | 17 | 179 | 2 | 285 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover | Total |
|---|---|---|---|---|---|---|---|
| Asian | 3 | 0 | 1 | 0 | 13 | 1 | 18 |
| Black or African-American | 5 | 2 | 4 | 2 | 38 | 0 | 51 |
| Native Hawaii or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 42 | 19 | 36 | 15 | 207 | 6 | 325 |
| Other | 0 | 2 | 0 | 0 | 4 | 0 | 6 |
| More than one race | 2 | 0 | 0 | 0 | 1 | 1 | 4 |
| Missing | 0 | 0 | 0 | 0 | 3 | 0 | 3 |
| Investigator Global Assessment (IGA) Baseline Score(Participants) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Cohort 2 Group 4: De Novo Participants | Cohort 1 Group 2: ARQ-154-116 Rollover | Total |
|---|---|---|---|---|---|---|---|
| 0 - Completely clear | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| 1 = Almost clear | 0 | 7 | 0 | 2 | 0 | 0 | 9 |
| 2 = Mild | 0 | 2 | 0 | 2 | 0 | 0 | 4 |
| 3 = Moderate | 44 | 11 | 38 | 13 | 235 | 5 | 346 |
| 4 = Severe | 8 | 1 | 3 | 0 | 32 | 3 | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Nov 2022, 29 months.
Results were first posted in Jun 2024, 1 year 6 months after primary completion. A results delay was requested in Oct 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARQ-154
Arcutis Biotherapeutics, Inc. →